Preclinical Development Plans and Regulatory Services | SRI International
This is an archived website. Go to the current SRI website

Toggle Menu

Preclinical Development Plans and Regulatory Services

Navigating the drug development process from early discovery to Phase I clinical trials can be complex and costly. Success requires a well-organized preclinical development plan.

To guide clients to a successful Investigational New Drug application (IND), SRI's Pharmaceutical Regulatory Services team partners with pharmaceutical and biotechnology companies, universities, and the government to prepare for Phase I-enabling studies. SRI researchers prepare, review, deliver, and follow the progress of the preclinical development plan and the documentation required for clients' pre-IND and IND submissions to assure compliance with Food and Drug Administration (FDA) regulations and protocols.

SRI can help you to

  • Refine preclinical program objectives

  • Develop a regulatory strategy

  • Review data and perform gap analyses

  • Design preclinical development testing to support an IND application

  • Design a risk management and contingency plan

SRI can create a Preclinical Development Plan (PDP) that defines a specific strategy and the study outlines to advance your lead candidate from the discovery stage to IND submission and initiation of Phase I clinical trials.

SRI's Regulatory Affairs Department can also

  • Provide drug/device development project management

  • Assist in preparing your organization for a pre-IND meeting with FDA

  • Prepare, assemble, and index an original IND for FDA submission

  • Coordinate and assemble the manufacturing, preclinical, and clinical documents for review and prepare an IND application

  • Prepare and update Master Files

  • Prepare and update Investigator's brochure

  • Prepare Annual Reports

  • Provide additional submissions and amendments as necessary for successful filling and maintenance of an IND

Marketed drugs discovered at SRI—proof of successful outcomes—include:

  • Bexarotene, for the treatment of cutaneous T-cell lymphoma

  • Halofantrine, an antimalarial drug

  • Pralatrexate, for the treatment of peripheral T-cell lymphoma

  • Vidarabine, an antiviral drug


Innovative Science Overcomes Formulation Challenges

Innovative Science Overcomes Formulation Challenges

Partnering to Advance Therapy for Radiation Exposure

Partnering to Advance Therapy for Radiation Exposure